类风湿关节炎相关间质性肺病25年预后改善:英国多中心研究
该研究分析英国18个中心25年间290例RA-ILD患者,发现全因死亡率30%、呼吸相关死亡率18%,均高于RA对照组。随诊断年代四分位组预后改善,死亡中位年龄从63岁升至78岁。抗TNF治疗与全因死亡风险升高相关,利妥昔单抗或霉酚酸酯治疗者风险较低。
要点
- RA-ILD患者全因死亡率30%、呼吸相关死亡率18%,高于RA对照的21%和7%。
- 25年间预后改善,死亡中位年龄从63岁升至78岁。
- 抗TNF治疗与全因死亡风险升高相关,利妥昔单抗或霉酚酸酯治疗者风险较低。
核心结论
- RA-ILD患者生存率在25年间改善,可能与非TNF生物制剂及免疫抑制剂使用增加有关。
研究设计与样本
- 英国18个中心25年回顾性多中心研究,纳入符合RA和ILD标准的290例患者,比较RA-ILD与RA对照的死亡率和药物影响。
主要发现
- RA-ILD全因死亡率为30%、呼吸相关死亡率为18%,RA对照分别为21%和7%(P=0.02)。
- 随诊断年代四分位组预后改善,死亡中位年龄从63岁升至78岁(P=0.01)。
- 抗TNF治疗者全因死亡相对风险升高[RR 2.09(1.1-4.0),P=0.03]。
- 利妥昔单抗治疗者RR为0.52(0.1-2.1),霉酚酸酯治疗者RR为0.65(0.2-2.0)。
- 以利妥昔单抗为首个生物制剂者3年、5年、7年生存率分别为92%、82%、80%,高于以抗TNF为首个生物制剂者的82%、76%、64%(P=0.037)。
关键数值与推荐
- RA-ILD全因死亡率30%、呼吸相关死亡率18%,RA对照分别为21%和7%(P=0.02)。
- 死亡中位年龄从63岁升至78岁(P=0.01)。
- 抗TNF治疗全因死亡RR 2.09(1.1-4.0),P=0.03。
临床怎么用
- RA-ILD患者预后较前改善,但死亡率仍高于RA对照,需关注呼吸相关死亡。
- 选择生物制剂时,抗TNF治疗与死亡风险升高相关,利妥昔单抗可能生存更优。
局限性
- 回顾性多中心研究,药物对死亡率的影响可能受混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study explores whether the prognosis of interstitial lung disease in rheumatoid arthritis (RA-ILD) has improved over time and assesses the potential influence of drug therapy in a large multicentre UK network. METHODS: We analysed data from 18 UK centres on patients meeting criteria for both RA and ILD diagnosed over a 25-year period. Data included age, disease duration, outcome and cause of death. We compared all cause and respiratory mortality between RA controls and RA-ILD patients, assessing the influence of specific drugs on mortality in four quartiles based on year of diagnosis. RESULTS: A total of 290 RA-ILD patients were identified. All cause (respiratory) mortality was increased at 30% (18%) compared with controls 21% (7%) (P =0.02). Overall, prognosis improved over quartiles with median age at death rising from 63 years to 78 years (P =0.01). No effect on mortality was detected as a result of DMARD use in RA-ILD. Relative risk (RR) of death from any cause was increased among patients who had received anti-TNF therapy [2.09 (1.1-4.0)] P =0.03, while RR was lower in those treated with rituximab [0.52(0.1-2.1)] or mycophenolate [0.65 (0.2-2.0)]. Patients receiving rituximab as their first biologic had longer three (92%), five (82%) and seven year (80%) survival than those whose first biologic was an anti-TNF agent (82%, 76% and 64%, respectively) (P =0.037). DISCUSSION: This large retrospective multicentre study demonstrates survival of patients with RA-ILD has improved. This may relate to the increasing use of specific immunosuppressive and biologic agents.
引用
- Kelly CA, Nisar M, Arthanari S, et al. Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study. Rheumatology (Oxford). 2021. PMID: 33150434. doi:10.1093/rheumatology/keaa577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。